UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• UBS AM decreased its position in Regeneron Pharmaceuticals by 4.2%, selling 41,728 shares and now owning 940,336 shares worth approximately $596.4 million.
• Regeneron reported $12.89 EPS, beating estimates by $4.46, with quarterly revenue of $3.68 billion, a 3.6% increase year-over-year.
• The company declared a quarterly dividend of $0.88, paid on September 3rd, representing an annualized dividend of $3.52 with a yield of 0.6%.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 940,336 shares of the biopharmaceutical company's stock after selling 41,728 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.87% of Regeneron Pharmaceuticals worth $596,389,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Adirondack Trust Co. increased its position in shares of Regeneron Pharmaceuticals by 4.2% during the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after buying an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV grew its position in shares of Regeneron Pharmaceuticals by 9.5% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after acquiring an additional 19 shares during the period. Private Trust Co. NA lifted its position in shares of Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after acquiring an additional 19 shares in the last quarter. Finally, Proficio Capital Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN stock opened at $556.53 on Wednesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The business's fifty day moving average price is $563.69 and its 200 day moving average price is $581.96. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,170.58. The firm has a market capitalization of $58.99 billion, a PE ratio of 14.03, a P/E/G ratio of 1.87 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 earnings per share. The company's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on REGN shares. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Sanford C. Bernstein upped their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.